EP0880591A1 - Muteines de thrombine s'utilisant comme antidote d'inhibiteurs de thrombine - Google Patents

Muteines de thrombine s'utilisant comme antidote d'inhibiteurs de thrombine

Info

Publication number
EP0880591A1
EP0880591A1 EP97903254A EP97903254A EP0880591A1 EP 0880591 A1 EP0880591 A1 EP 0880591A1 EP 97903254 A EP97903254 A EP 97903254A EP 97903254 A EP97903254 A EP 97903254A EP 0880591 A1 EP0880591 A1 EP 0880591A1
Authority
EP
European Patent Office
Prior art keywords
thrombin
seq
gly
ala
muteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97903254A
Other languages
German (de)
English (en)
Inventor
Martin Raditsch
Thomas Friedrich
Claus Bollschweiler
Martin Schmidt
Hans Wolfgang HÖFFKEN
Jürgen Schweden
Klaus Rübsamen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF SE
Original Assignee
BASF SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BASF SE filed Critical BASF SE
Publication of EP0880591A1 publication Critical patent/EP0880591A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6429—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21005—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • Thrombin muteins as an antidote for thrombin inhibitors
  • the present invention relates to new thrombin muteins, their preparation and their use as an antidote for thrombin inhibitors.
  • Anticoagulants which act on the principle of direct thrombin inhibition are becoming increasingly important for antithrombotic therapy.
  • An imperative prerequisite for the broad use of anticoagulants is the possibility of neutralizing the effect in the event of overdoses, in the event of impaired breakdown or slow excretion, in order to avoid the then threatening hemorrhagic side effects, such as bleeding in the area of the peritoneum , the pericardium, the pleura.
  • highly effective antidotes are available for heparin with protamine sulfate, polylysine and platelet factor 4
  • there is currently no antidote suitable for use in humans for neutralizing thrombin inhibitors there is currently no antidote suitable for use in humans for neutralizing thrombin inhibitors.
  • Markwardt Thrombosis Research, Voi 74, No 1, ppl-23, 1994
  • thrombines thrombin derivatives. Examples of these are thrombin, thrombin-2-macroglobulin complexes and meizothrombin.
  • chemically inactivated thrombines such as, for. B. DFP thrombin or benzoyl thrombin for the neutralization of hirudin (Markwardt, Pharmazie 1989; 44; 648-649).
  • a genetically engineered, enzymatically inactive thrombin is described by Lentz (Lentz et al, JBC; Voi 266, No 15, pp 9598-9604).
  • Lentz Lentz et al, JBC; Voi 266, No 15, pp 9598-9604
  • the replacement of the serine residue at position 205 (position 525 in SEQ ID NO: 14) required for catalysis with alanine leads to an enzymatically inactive thrombin variant which has no cleavage activity towards synthetic substrates and the natural substrate fibrinogen has (Lentz et al, JBC Voi 266, No. 15, page 9598-9604), but has a lower binding affinity to the thrombin inhibitor dansylarginin-N- (3-ethyl-l, 5-pentanediyl) amide. 5
  • thrombin muteins are not suitable as antidotes for thrombin inhibitors, since they either have too little affinity for the thrombin inhibitor or they have too high a binding and enzymatic activity with regard to fibrinogesn.
  • the object was therefore to provide new thrombin muteins which are largely inactive enzymatically, have good binding of the thrombin inhibitor and at the same time bind the natural substrate fibrionogen with less affinity than the unmodified thrombin.
  • the invention relates to thrombin muteins which have the following sequence differences compared to natural thrombin 5 (a) Exchange of a Gly for Ala, the Gly being in the sequence environment Tyr-Gly-Phe and having the position 558 in natural human prothrombin (SEQ ID NO: 14);
  • the new thrombin muteins can be prepared starting from known natural thrombins, such as human thrombin, and other mammals, for example primates, cattle, pigs, dogs, cats, mice, rats.
  • Natural thrombin is to be understood as a polypeptide sequence which has thrombin activity and occurs naturally in an organism.
  • Thrombin muteins are not only to be understood as disulfide-bridged two-chain molecules (A and B chain), but also one-chain form molecules such as prethrombin or proteins that are only made up of the B chain or parts of the B chain, preferably from N and / or C-terminally shortened B chains. It is crucial for the thrombin muteins according to the invention that the effectiveness with regard to thrombin inhibitor binding is present.
  • the thrombin muteins according to the invention can also be prepared starting from known proteolysis products of thrombin, for example ⁇ -thrombin, ⁇ -thrombin, ⁇ -thrombin or else precursors of thrombin such as prothrombin, prothrombin intermediates or also meizothrombines, which then, if appropriate, by suitable cleavage methods can be converted into the active thrombin molecules, for example by means of factor Xa, fractions of the snake venom from Echis carinatus or also Oxyranus scutellatus.
  • the thrombin muteins according to the invention are suitable for neutralizing hirudin, hirudin derivatives or other thrombin inhibitors. Genetic engineering is preferred in which a corresponding gene for the thrombin mutein is produced and this gene is expressed in a suitable host organism.
  • the novel thrombin muteins have to natural thrombin least two differences in sequence, the first differences d replacement of a glycine residue to an alanine residue.
  • the position of the exchange depends on the origin of the natural starting thrombin. However, it is the glycine position which is in the sequence environment Tyr-Gly-Phe and which has the position 558 in natural human prothrombin (SEQ ID NO: 14).
  • the second sequence difference is either an exchange or a deletion of an amino acid residue at one of the three positions (His, Asp, Ser) that form the catalytic triad of the protease thrombin.
  • these positions are positions 363 for His, 419 for Asp and 525 for Ser.
  • these positions can be shifted somewhat depending on the total length of the molecule.
  • the sequence environment i.e. however, the amino acid residues before and after the corresponding amino acid are preserved in the thrombine, and it is therefore easily possible to determine the exact position of the corresponding amino acid residue using the sequence environment.
  • the thrombin muteins according to the invention can also have several changes (deletions or substitutions) on the catalytic triad. Thrombin muteins which have a single change in the catalytic triad are preferred.
  • Preferred changes are those in which the amino acids of the catalytic triad have been substituted.
  • Preferred substitutions for the histidine residue are those with polar or hydrophobic amino acids, in particular with Phe, Tyr, Ala or Val.
  • the aspartate residue is preferably substituted with other polar amino acids, for example gin or Asn.
  • Thrombin muteins in which the serine residue is changed are particularly preferred, in particular substitutions of the serine by amino acids which have no hydroxyl function, in particular those which have a space filling similar to that of Ser. Substitution Ser to Ala is particularly preferred.
  • the effectiveness of the thrombin muteins can be further improved by introducing further changes to the molecule.
  • the proteolytic stability continues is improved, for example to allow a longer duration of action in vivo.
  • the basic residues Arg 393, Lys 465, Arg 390 or Arg 382 can be exchanged for another non-basic amino acid.
  • the invention further relates to nucleic acid sequences, in particular DNA sequences, which code for the thrombin proteins described. These can easily be determined by back-translating the polypeptide sequence into the corresponding DNA sequence according to the genetic code. Those codons which lead to a good expression in the desired host organism are preferably used.
  • the nucleic acid sequence can be produced either from the natural thrombin sequence by site-specific mutagenesis or else fully synthetically by DNA synthesis.
  • the thrombin muteins according to the invention are particularly suitable as an antidote for thrombin inhibitors such as hirudins, hirudin derivatives and low-molecular thrombin inhibitors.
  • Hirudinen is shown both in animal experiments and in humans.
  • hirudins there are also numerous hirudin muteins and isohirudins that have sequence changes compared to natural hirudin.
  • hirudins are therefore also to be understood as those hududins which carry one or more sequence changes with respect to the hirudin from Hirudo medicinalis and which have at least an equally high affinity for thrombin.
  • Hirudins are easily accessible using genetic engineering methods. Their half-life in humans is about 45 minutes.
  • hirudin in which the pharmacokinetics of hirudin have been modified by chemical modification are also known. Markwardt describes conjugates from dextran and hirudin with a longer duration of action. Long-acting polymer conjugates are known from EP 345616, EP 502962 and EP 557199. WO 9515183 describes long-acting hydrophobic hirudin derivatives. Depot forms and long-acting hirudin dimers (WO 9504823) are also known. Other thrombin inhibitors are low molecular weight Thrombin inhibitors, which are known for example from EP 236164, DE 2801478, EP 293881 or EP 185390.
  • thrombin inhibitors are recombinantly produced desulfato hirudins, hirudin muteins, polymer-modified hirudins such as. B. dextran-hirudins, PEG-hirudins, hydrophobically derivatized hirudins and hirudin muteins with an extended duration of action.
  • the new thrombins can be used to antagonize hirudisins, shortened hirudins, and hirudin analogs derived from hirudin and its partial sequences, e.g. Hiruloge or C-terminal hirudin peptides.
  • Other peptide thrombin inhibitors which e.g. have been described from blood-sucking organisms and are used for therapy after genetic engineering, such as. B. Rhodniin; Infestine.
  • neutralizable thrombin inhibitors are also synthetic, preferably low molecular weight thrombin inhibitors, such as, for example, derivatives of the tripeptide D-Phe-Pro-Arg, NAPAP, boronic acid derivatives, arginals or benzamidine derivatives.
  • the thrombin muteins according to the invention neutralize the thrombin inhibitors better than the principles described hitherto for neutralizing thrombin inhibitors.
  • the thrombins according to the invention are safe to use even in the event of an overdose, and therefore enable rapid and effective neutralization of the thrombin inhibitors in emergency situations.
  • the thrombin muteins according to the invention are in one for parenteral administration, i.e. suitable form for subcutaneous, intramuscular or intravenous administration. Intravenous administration is preferred. If appropriate, the thrombin muteins according to the invention can also be administered as a continuous infusion.
  • the amount of inactive thrombin to be administered is e.g. depending on the extent of the overdose, body weight and the chosen form of administration. The extent of the overdose can be determined by a person skilled in the art before or during the use of thrombin by means of suitable tests.
  • the thrombin muteins according to the invention can be produced with the aid of genetic engineering methods. Genetically engineered production of a precursor form of thrombin mutein (analogous to Prothrombin) from which the thrombin mutein is released by means of proteolytic activation.
  • Another preferred form of production, especially for thrombin muteins that only consist of the B chain, is the expression of the gene for the B chain modified according to the invention in microorganisms, preferably in bacteria such as E. coli.
  • the expression product obtained may have to be renatured using methods familiar to the person skilled in the art in order to obtain an effective thrombin mutein molecule.
  • it has also proven to be advantageous to replace the Cys residue which contributes to the S-S bridging in natural human thrombin with another amino acid residue, for example Ser or Ala.
  • Prothrombin was prepared according to the publication by Degen et al (Biochemistry, 1983, 22, p 2087 -. 97) defined from a human liver cDNA bank Loo.
  • the muteins according to the invention were produced by targeted mutagenesis in the thrombin part.
  • the codon GGC for the amino acid (As) glycine in position 558 (SEQ ID NO: 14) of the human prothrombin was mutated into the codon GCC for the As Ala by targeted mutagenesis.
  • the oligonucleotide SEQ ID NO: 5 in the direction of the gene and the complementary oligonucleotide SEQ ID NO: 6 in the opposite direction were synthesized with the corresponding nucleotide exchange.
  • the oligonucleotide SEQ ID NO: 1 was synthesized in the direction corresponding to the 5 'end of the prothrombin gene.
  • the sequence for the restriction site Eco R1 was additionally added to this at the 5 'end.
  • the oligonucleotide SEQ ID NO: 2 was synthesized in the opposite direction corresponding to the 3 'end of the thrombin gene, and the sequence for the restriction site Eco R1 was also added to it at the 5' end.
  • the codon AGT for the As Ser in position 525 (SEQ ID NO: 14) of the human prothrombin became the codon GCT for the As Ala and the codon GGC for the As Gly in position 558 (SEQ ID NO: 14) Codon GCC mutated for the As Ala.
  • a PCR was carried out on the basis of the prothrombin mutein DNA from Example 1 and the oligo SEQ ID NO: 3 with the corresponding nucleotide exchange for Ala at position 525 in the sense direction and the oligo SEQ ID NO: 2 (3'end prothrombin).
  • the test conditions corresponded to those from Example 1.
  • a second PCR was carried out with the oligo SEQ ID NO: 4 complementary to SEQ ID NO: 3 and the oligo SEQ ID NO: 1 (5'end prothrombin).
  • the DNA fragments obtained in this way were denatured, hybridized, filled into a double strand and then, according to example 1, a further PCR was carried out with the external oligos SEQ ID NO: 1 and SEQ ID NO: 2.
  • the prothombin mutein cDNA thus prepared was purified, cut with Eco Rl, cloned into the vector pUC 18 and sequenced as a control.
  • the codon AGT for the As His in position 363 (SEQ ID NO: 14) of the human prothrombin became the codon GCA for the As Ala and the codon GGC for the AS Gly in position 558 (SEQ ID NO: 14) Codon GCC mutated for the As Ala.
  • a PCR was carried out on the basis of the prothrombin mutein DNA from Example 1 and the oligo SEQ ID NO: 10 with the corresponding nucleotide exchange for the Ala at position 363 in the sense direction and the oligo SEQ ID NO: 2 (3'end prothrombin).
  • the test conditions corresponded to those from Example 1.
  • a second PCR was carried out with the oligo SEQ ID NO: 11 complementary to SEQ ID NO: 10 and the oligo SEQ ID NO: 1 (5'end prothrombin).
  • the DNA fragments obtained in this way were denatured, hybridized, filled in to form a double strand and then a further PCR was carried out in accordance with Example 1 using the external oligos SEQ ID NO: 1 and SEQ ID NO: 2.
  • the prothombin mutein cDNA thus prepared was purified, cut with Eco Rl, cloned into the vector pUC 18 and sequenced as a control.
  • the codon GAC for the As Asp in position 419 (SEQ ID NO: 14) of the human prothrombin became the codon GCA for the As Asn and the codon GGC for the AS Gly in position 558 (SEQ ID NO: 14) Codon GCC mutated for the As Ala.
  • a PCR was carried out on the basis of the prothrombin mutein DNA from Example 1 and the oligo SEQ ID NO: 12 with the corresponding nucleotide exchange for the Asn at position 419 and the oligo SEQ ID NO: 2 (3'end prothrombin).
  • the test conditions corresponded to those from Example 1.
  • a second PCR was carried out with the oligo SEQ ID NO: 13 complementary to SEQ ID NO: 12 and the oligo SEQ ID NO: 1 (5'end prothrombin).
  • the DNA fragments thus obtained were denatured, hybridized, filled in to a double strand and then correspondingly
  • Example 1 carried out a further PCR with the external oligos SEQ ID NO: 1 and SEQ ID NO: 2.
  • the prothrombin thus produced - mutein cDNA was purified, then cut with Eco RI, cloned into the vector pUC 18 an d to control sequenced.
  • the codon AGT for the As Ser in position 525 (SEQ ID NO: 14) of the human prothrombin was mutated to the codon GCT for the As Ala.
  • a PCR was carried out on the basis of the prothrombin DNA and the oligo SEQ ID NO: 3 with the corresponding nucleotide exchange for the Ala at position 525 in the sense as well as the oligo SEQ ID NO: 2 (3'end prothrombin).
  • a second PCR was carried out with the oligo SEQ ID NO: 4 complementary to SEQ ID NO: 3 and the oligo SEQ ID NO: 1 (5'end prothrombin).
  • the DNA fragments obtained in this way were denatured, hybridized, filled into a double strand and then a further PCR was carried out with the external oligos SEQ ID NO: 1 and SEQ ID NO: 2.
  • the prothombin mutein cDNA thus prepared was purified, cut with Eco Rl, cloned into the vector pUC 18 and sequenced as a control.
  • the secretion leader of the sequence of the human tPA gene was added to the 5 'ends of the mutated prothrombin cDNAs (see Example 1 to 5) (Pennica et al Nature 301, 214-221, 1983).
  • the tPA sector was created with the synthetic oligonucleotides SEQ ID NO: 9 (5 'end of the tPA leader and Eco RI site) and SEQ ID NO: 8 (3' end tPA leader, 5 'end prothrombin) - tion leader cDNA amplified on the basis of PCR.
  • the mutated prothrombin mutein fragments were amplified with the oligo SEQ ID NO: 7 and SEQ ID NO: 2, which are complementary to SEQ ID NO: 8.
  • the tPA leader fragments were added to the respective prothrombin mother fragments.
  • the batches were denatured, hybridized, filled up to the double strand and with a further PCR with the oligonucleotides SEQ ID NO: 9 and SEQ ID NO: 2 the respective tPA leader prothrombin mutein DNAs were produced. These were cut with Eco R1, cloned into pUC 18 and sequenced for control. 5
  • these DNAs were cut out of the pUC 18 vectors with Eco Rl, isolated and inserted into the Eco Rl cleavage site of the vector pc DNA3 neo (Invitrogen, San Diego, USA).
  • the transcription of the prothrombin cDNA in this vector is under the control of the strong cytomegalovirus promoter.
  • the selection for transfected cells is carried out via the neomycin resistance gene located in the plasmid, which only allows G 418-resistant colonies to grow.
  • the DNA of the expression vectors was transfected with lipofectamine (25 Gibco; Life Technologies GmbH; Dieselstrasse 5, 76334 Eggenstein, Germany; No. 530-8324SA) in mammalian cells.
  • the cells used were CHO-Kl (ATCC CCL 61); 293 (ATCC CRL 1573).
  • the cells were split, so that 20 to 100 10 cm petri dishes were sown from a well of a 6-well plate.
  • the recombinant cells were started by treatment with G418 (Gibco, 1200 ⁇ g / ml in medium).
  • the resistant colonies obtained were separated by the "cloning cylinder" method and, after growing up and reaching sufficient cell numbers, were examined for expression of the corresponding thrombin muteins.
  • the medium was aspirated from confluent cells and replaced by fresh, serum-free medium. After fixed times such as after 24 hours, 48 hours, the incubated cell culture supernatant was removed and tested for the presence of the prothrombin using the ELISA.
  • Some of the recombinant cells obtained were cloned in microtiter plates to increase expression by separation.
  • DMEM Gibco No. 11880-028
  • F12 Gibco No. 21765-029 mixture consists of equal parts by volume
  • the DMEM used for this purpose was free of phenol red.
  • harvested After two or three days there was a change of media (“harvest”) in order to harvest the cell culture supernatant containing prothrombin mutein. In this way it was possible to harvest up to 10 times from a culture vessel. Different harvests from different Different culture vessels were combined to achieve a volume acceptable for purification.
  • the serum-free cell culture supernatant was removed after a differently long culture period.
  • the prothrombin present in the cell culture supernatant was cleaved by means of snake venom (Sigma; Cat. No. V3129). Each approach was carried out as follows:
  • the cleavage batches were incubated for 45 minutes at room temperature.
  • the resulting thrombin was then characterized in various tests.
  • 0.1 ml / well streptavidin-peroxidase complex (B.M. 1089153); 1: 10,000 diluted in 0.1% BSA / 0.05% Tween 20 / PBS; 30 minutes / RT wash as above 0.1 ml / well peroxidase substrate Stop reaction with 0.1 ml / well 2 M H2S04 Measure the absorption at 450 nm peroxidase substrate: 0.1 ml TMB solution (42 mM TMB in DMSO) and 10 Mix ml of substrate buffer (0.1 M Na acetate pH 4.9); then add 14.7 ⁇ l of 3% H202
  • Adjuvant (Sigma F5881) day 14 200 ⁇ g human thrombin in 0.5 ml PBS / incomplete Freund's
  • Adjuvant (Sigma F5506) day 28 200 ⁇ g human thrombin in 0.5 ml PBS / incomplete Freund's
  • Adjuvant day 42 200 ⁇ g human thrombin in 0.5 ml PBS
  • the polyclonal rabbit antibodies from the serum obtained were purified via protein A Sepharose (according to the manufacturer Pharmacia) with a yield of 65 mg IgG / 10 ml serum. Before biotinylation, the antibodies were dialyzed against 0.05 M NaHC03 pH 9.0 (2x 2 1), then addition of 200 ⁇ l Biotin-X-NHS ester (Calbiochem 203189; 1 mg / ml H20) per 600 ⁇ l antibody ( 2.4 mg / ml) and shake for 2 hours / RT. Finally, dialysis was performed 3 times against PBS. A sandwich ELISA was set up using the antibodies obtained:
  • biotinylated anti-thrombin AK 1 200, diluted in 1% BSA / PBS / 0.05% Tween 20; 2 hours / RT - wash as above
  • Figure 1 shows the absorption (OD) against the thrombin concentration.
  • Peroxidase substrate Mix 0.1 ml TMB solution (42 mM in DMSO) and 10 ml substrate buffer (0.1 M Na acetate pH 4.9); then add 14.7 ⁇ l of 3% H202.
  • biotinylated anti-thrombin antibody 1 200; diluted in 0.1% BSA / 0.05% Tween 20 / PBS; 2-4 hours / RT Wash like above
  • 10 peroxidase substrate Mix 0.1 ml TMB solution (42 mM TMB in DMSO) and 10 ml substrate buffer (0.1 M Na acetate pH 4.9); then add 14.7 ⁇ l 3% H 2 0 2 .
  • the activity of the thrombin muteins is determined by cleaving a tripeptide. The following pipetting scheme is used for this:
  • the batches are incubated at 37 ° C. for 10-15 minutes.
  • the absorption is then measured at a wavelength of 405 nM and the amount of thrombin is determined on the basis of a calibration curve between 0.01 and 1 U / ml.
  • 35 1 of the prothrombin-containing cell culture supernatant from the CHO cell culture is first concentrated to 400 ml by ultrafiltration at 4C (SPS 400 membrane, Fresenius, St. Wendel) and then diafiltered against 10 mM Tris pH 7.5 until the guide
  • the fractions containing prothrombin are identified by means of ELISA.
  • the prothrombin mutein elutes from 280 mM NaCl.
  • About 150-200 mg of protein are isolated from this column.
  • the thrombin-containing cleavage from Example 14 is then applied to a heparin-Sepharose column (14 cm ⁇ 1 cm, Pharmacia) at a flow rate of 38 cm / h. After washing the column with 20 ml of 20 mM Na phosphate, 0.1 M NaCl pH 7.5 0.01%
  • hirudin The antidote effect of the inactive recombinant thrombins on hirudin was demonstrated in a thrombin activity test.
  • hirudin The thrombin mutein to be tested; active thrombin and S-2238 incubated together.
  • the principle on which this test is based is the neutralization (or competition) of hirudin by the inactive thrombin to be tested, and the resulting higher activity of the active thrombin.
  • hirudin HL20 1.5 U / ml
  • 0.1% BSA in TBS pH 7.5 100 ⁇ l of thrombin mutein (prepared in Example 2) were preincubated for 5 minutes at room temperature.
  • 50 ⁇ l of active thrombin 0.5 U / ml
  • the reaction was started by adding 50 ⁇ l of S-2238 (1 mg / ml in H 2 0; Chromogenix, Mölndal; Sweden). The batches were incubated at 37 ° C. for 15 minutes. The absorption was then measured at a wavelength of 410 nm. Neutralization of the hirudin by the inactive thrombin mutein led to an increase in absorption (Fig. 2).
  • antithrombin activity was determined as described in Spanagel et al., Blood Coagulation Fibrinolysis, 1991, 2 :, 121-127.
  • Anticoagulant activity was determined using the Pathromtin system (Behring).
  • MOLECULE TYPE cDNA to mRNS
  • HYPOTHETICAL NO
  • MOLECULE TYPE cDNA to mRNA
  • HYPOTHETICAL NO
  • ANTISENSE NO
  • MOLECULE TYPE cDNA to mRNA
  • HYPOTHETICAL NO
  • ANTISENSE NO
  • SEQUENCE DESCRIPTION SEQ ID NO: 3: GGATGCCTGT GAAGGTGACG CTGGGGGACC CTTTGTCATQ 40 (2 NO) INFORMATION ON SEQ ID NO: 3
  • MOLECULE TYPE cDNA to mRNA
  • HYPOTHETICAL NO
  • ANTISENSE NO
  • SEQUENCE DESCRIPTION SEQ ID NO: 5:
  • MOLECULE TYPE cDNA to mRNA
  • HYPOTHETICAL NO
  • ANTISENSE NO
  • SEQUENCE DESCRIPTION SEQ ID NO: 6: GGAACACATG TGTGTAGAAG GCATATTTCC CATCCCGGTC 40 (2) INFORMATION ON SEQ ID NO: 7:
  • MOLECULE TYPE cDNA to mRNA
  • HYPOTHETICAL NO
  • ANTISENSE NO
  • SEQUENCE DESCRIPTION SEQ ID NO: 11: CGGGTACAGG AGGCACACGG CGGCGGTGAG 30 (2) INFORMATION ON SEQ ID NO: 12:
  • MOLECULE TYPE cDNA to mRNA
  • HYPOTHETICAL NO
  • ANTISENSE NO
  • SEQUENCE DESCRIPTION SEQ ID NO: 12: GAACCTGGAC CGGAACATTG CCCTGAT 27
  • MOLECULE TYPE cDNA to mRNA
  • HYPOTHETICAL NO
  • ANTISENSE NO
  • SEQUENCE DESCRIPTION SEQ ID NO: 13: ATCAGGGCAA TGTTCCGGTC CAGGTTC 27

Abstract

L'invention concerne des mutéines de thrombine qui présentent, comparativement à la thrombine naturelle, les différences séquentielles suivantes: (a) substitution d'un Gly après Ala, ledit Gly se trouvant dans l'environnement séquentiel Tyr-Gly-Phe et ayant la position 558 dans la thrombine humaine naturelle (SEQ ID n°14); (b) au moins une substitution ou une délétion des radicaux suivants: (b1) His qui se situe dans l'environnement séquentiel Ala-His-Cys et a la position 363 dans la thrombine humaine naturelle (SEQ ID n°14); (b2) Asp qui se situe dans l'environnement séquentiel Arg-Asp-Ile et a la position 419 dans la thrombine humaine naturelle (SEQ ID n°14); (b3) Ser qui se situe dans l'environnement séquentiel Asp-Ser-Gly et a la position 525 dans la thrombine humaine naturelle (SEQ ID n°14). L'invention concerne par ailleurs leur utilisation comme antidote.
EP97903254A 1996-02-12 1997-02-11 Muteines de thrombine s'utilisant comme antidote d'inhibiteurs de thrombine Withdrawn EP0880591A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19605126A DE19605126A1 (de) 1996-02-12 1996-02-12 Thrombinmuteine als Antidot für Thrombininhibitoren
DE19605126 1996-02-12
PCT/EP1997/000612 WO1997029198A1 (fr) 1996-02-12 1997-02-11 Muteines de thrombine s'utilisant comme antidote d'inhibiteurs de thrombine

Publications (1)

Publication Number Publication Date
EP0880591A1 true EP0880591A1 (fr) 1998-12-02

Family

ID=7785198

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97903254A Withdrawn EP0880591A1 (fr) 1996-02-12 1997-02-11 Muteines de thrombine s'utilisant comme antidote d'inhibiteurs de thrombine

Country Status (18)

Country Link
US (1) US6060300A (fr)
EP (1) EP0880591A1 (fr)
JP (1) JPH11512621A (fr)
KR (1) KR19990082479A (fr)
CN (1) CN1211280A (fr)
AR (1) AR005797A1 (fr)
AU (1) AU1768497A (fr)
BR (1) BR9707280A (fr)
CA (1) CA2245546A1 (fr)
CO (1) CO4600682A1 (fr)
CZ (1) CZ247798A3 (fr)
DE (1) DE19605126A1 (fr)
HR (1) HRP970077A2 (fr)
HU (1) HUP9900574A2 (fr)
IL (1) IL125077A0 (fr)
NO (1) NO983677L (fr)
WO (1) WO1997029198A1 (fr)
ZA (1) ZA971107B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20000018933A (ko) * 1998-09-07 2000-04-06 김승수 내피세포 성장억제 활성을 가지는 사람 프로트롬빈 크링글단백질 및 이를 암호하는 유전자
GB2355161B (en) * 1999-10-05 2001-09-12 3Com Corp Network device incorporating selective compression of stored data packets
KR20020008471A (ko) * 2000-07-20 2002-01-31 김승수 내피세포 성장 억제활성을 가지는 인간 프로트롬빈크링글, 그것의 재조합벡터 및 이를 발현하는 재조합 숙주
US20100159512A1 (en) * 2006-03-06 2010-06-24 Kurt Osther Method for the preparation of recombinant human thrombin and fibrinogen
KR20170100071A (ko) 2007-09-28 2017-09-01 포톨라 파마슈티컬스, 인코포레이티드 인자 Ｘａ 저해제에 대한 안티도트 및 그것을 사용하는 방법
MX2011004907A (es) 2008-11-14 2011-07-29 Portola Pharm Inc Antidotos para inhibidores del factor xa y metodos para el uso de los mismos en combinacion con agentes de coagulacion de sangre.
ES2607935T3 (es) 2009-03-30 2017-04-04 Portola Pharmaceuticals, Inc. Antídotos para inhibidores del factor Xa y procedimientos de uso de los mismos
CA2767858C (fr) 2009-07-15 2019-02-12 Portola Pharmaceuticals, Inc. Formulation de dose unique d'antidotes pour des inhibiteurs de facteur xa et procedes d'utilisation de celle-ci
ES2620421T3 (es) * 2009-10-30 2017-06-28 Senova Gesellschaft für Biowissenschaft und Technik mbH Peptidasas acopladas a polímero
AR079944A1 (es) 2010-01-20 2012-02-29 Boehringer Ingelheim Int Anticuerpo neutralizante de la actividad de un anticoagulante
SG193552A1 (en) 2011-03-30 2013-11-29 Boehringer Ingelheim Int Anticoagulant antidotes
SG11201609811TA (en) 2014-05-26 2016-12-29 Academisch Ziekenhuis Leiden Prohemostatic proteins for the treatment of bleeding

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4203965A1 (de) * 1992-02-11 1993-08-12 Max Planck Gesellschaft Antidot fuer hirudin und synthetische thrombininhibitoren

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9729198A1 *

Also Published As

Publication number Publication date
ZA971107B (en) 1998-08-11
WO1997029198A1 (fr) 1997-08-14
JPH11512621A (ja) 1999-11-02
CN1211280A (zh) 1999-03-17
CZ247798A3 (cs) 1999-03-17
KR19990082479A (ko) 1999-11-25
AU1768497A (en) 1997-08-28
CA2245546A1 (fr) 1997-08-14
BR9707280A (pt) 1999-07-20
DE19605126A1 (de) 1997-08-14
CO4600682A1 (es) 1998-05-08
NO983677D0 (no) 1998-08-11
NO983677L (no) 1998-08-11
HRP970077A2 (en) 1998-04-30
US6060300A (en) 2000-05-09
AR005797A1 (es) 1999-07-14
IL125077A0 (en) 1999-01-26
HUP9900574A2 (hu) 1999-06-28

Similar Documents

Publication Publication Date Title
DE69434332T2 (de) Thrombin mutanten
EP0966536B1 (fr) Analogues du facteur x dont le site de clivage donnant une protease est modifie
DE69333127T2 (de) Varianten des Gewebeplasminogenaktivators mit verbesserter therapeutischer Wirkung
EP1012303B1 (fr) Mutants du facteur x a deletion d'acides amines et analogues desdits mutants
EP0880591A1 (fr) Muteines de thrombine s'utilisant comme antidote d'inhibiteurs de thrombine
WO2003066842A2 (fr) Procede pour produire des proteines de recombinaison dans des micro-organismes
DD229151A5 (de) Verfahren zur herstellung von gewebeplasminogenaktivatoren
DE60038312T2 (de) Faktor x-analog mit einer verbesserten fähigkeit, aktiviert zu werden
EP0669394B1 (fr) Dérivés bifonctionels de l'urokinase ayant des propriétés améliorées fibrinolytiques et inhibant la thrombine
CS276245B6 (en) Process for preparing modification of one of hv1, hv2, hv3 hirudin forms
EP0568833B1 (fr) Mutants de l'antithrombine III humaine
EP0705901A2 (fr) Procédé de séparation du profacteur IX recombinant du facteur IX recombinant
EP0677107B1 (fr) Inhibiteur de thrombine provenant de salive de protostomiens
DD274053A5 (de) Verfahren zur Produktion eines menschlichen, einkettigen Plasminogenaktivators
EP0714982A2 (fr) Protéines hybrides, ayant des propriétés fibrinolytiques et inhibant la thrombine
EP0769050A1 (fr) Derives activateurs du plasminogene non glucosyles et leur utilisation en cas de risque eleve d'hemorragie
EP0496327A1 (fr) Polypeptides ayant l'activité de la prourokinase, plasmides codant pour les polypeptides, leur production et utilisation
EP0712934A2 (fr) Protéines avec une activité fibrinolytique et anticoagulante
EP0666315A1 (fr) Fragments de facteur 1X stabilisants de thrombocytes, leur préparation et leur utilisation, et médicaments les contenant
EP0819173B1 (fr) Mutant de l'inhibiteur du type erythrina caffra et son utilisation pour la purification des serine-proteases
EP0917567A1 (fr) Activateur du plasminogene activable par thrombine
DE4122688A1 (de) Amidierte fibrinolytische enzyme und ihre vorlaeufer und verfahren zu ihrer herstellung
DE4340798A1 (de) Thrombininhibitor aus Speichel von Protostomiern
DE4443273A1 (de) Verwendung der Proteasedomäne von humanem Plasminogenaktivator zur Behandlung von thromboembolischen Erkrankungen

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19980618

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE ES FI FR GB IT LI NL SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030901